|  |  |  | Model 1 |  | Model 2 |  | Model 3 |  | Model 4 |  |
---|---|---|---|---|---|---|---|---|---|---|---|
Genetic risk | Total no. of participants | No. of ARHL cases | Prevalence (%) | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value | OR (95% CI) | P-value |
Low | 75,322 | 15,453 | 20.52 | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | ||||
Intermediate | 225,879 | 52,060 | 23.05 | 1.16 (1.14–1.19) |  < .001 | 1.15 (1.12–1.17) |  < .001 | 1.14 (1.12–1.17) |  < .001 | 1.14 (1.11–1.17) |  < .001 |
High | 71,499 | 18,477 | 25.84 | 1.36 (1.33–1.40) |  < .001 | 1.35 (1.32–1.39) |  < .001 | 1.34 (1.31–1.38) |  < .001 | 1.34 (1.31–1.39) |  < .001 |
Very high | 3764 | 1076 | 28.59 | 1.58 (1.47–1.70) |  < .001 | 1.55 (1.43–1.68) |  < .001 | 1.49 (1.36–1.63) |  < .001 | 1.49 (1.36–1.62) |  < .001 |
perSD increase |  |  |  | 1.12 (1.11–1.13) |  < .001 | 1.12 (1.11–1.13) |  < .001 | 1.12 (1.11–1.13) |  < .001 | 1.12 (1.11–1.13) |  < .001 |